Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
Keith J AugustErin M GuestKaren LewingJ Allyson HaysAlan S GamisPublished in: Pediatric blood & cancer (2019)
In children with relapsed or refractory ALL, the addition of bortezomib to reinduction chemotherapy that includes mitoxantrone produces a complete response in the majority of cases and does not lead to excessive toxicity.
Keyphrases
- acute lymphoblastic leukemia
- multiple myeloma
- young adults
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- diffuse large b cell lymphoma
- hodgkin lymphoma
- oxidative stress
- newly diagnosed
- low dose
- high dose
- weight gain
- squamous cell carcinoma
- locally advanced
- physical activity
- combination therapy
- radiation therapy
- weight loss
- rectal cancer